Intranasal Administer as 0.1 mL/nostril. Active inhalation (ie, sniffing) is not required during administration. Adult ≤49 yr & childn ≥9 yr 1 dose (0.2 mL). Childn 2-8 yr 1 or 2 doses (0.2 mL each). Administer at least 1 mth apart if 2 doses.
History of severe allergic reaction (eg, anaphylaxis) to any component of the vaccine including egg protein, or after a previous dose of any influenza vaccine. Childn & adolescents ≤17 yr receiving aspirin or aspirin-containing therapy due to the association of Reye's syndrome w/ aspirin & wild-type influenza infection.
Potential anaphylactic reactions following vaccination. May not protect all vaccinees. Increased risk of wheezing following vaccination in childn <5 yr w/ recurrent wheezing & persons of any age w/ asthma. Has not been studied in persons w/ severe asthma or active wheezing. Carefully consider potential benefits & risks of vaccination w/ FluMist Trivalent if Guillain-Barré syndrome has occurred w/in 6 wk of any prior influenza vaccination. Effectiveness has not been studied in immunocompromised persons. Safety has not been established in individuals w/ underlying medical conditions that may predispose them to complications following wild-type influenza infection. Not approved for use in childn <2 yr & elderly ≥65 yr.
Avoid aspirin-containing therapy in childn & adolescents ≤17 yr during the 1st 4 wk after vaccination unless clearly needed. Reduced effectiveness w/ antiviral drugs that are active against influenza A &/or B viruses if administered w/in 48 hr before or w/in 2 wk after vaccination.
Sign Out
